X0508 4 2024-05-03 0 0001607678 Viking Therapeutics, Inc. VKTX 0001264949 ZANTE GREG C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer 1 Common Stock, par value $0.00001 per share 2024-05-03 4 M 0 4249 4.68 A 211610 D Common Stock, par value $0.00001 per share 2024-05-03 4 M 0 30000 4.88 A 241610 D Common Stock, par value $0.00001 per share 2024-05-03 4 S 0 3101 73.4881 D 238509 D Common Stock, par value $0.00001 per share 2024-05-03 4 S 0 45570 74.4447 D 192939 D Common Stock, par value $0.00001 per share 2024-05-03 4 S 0 17238 75.4868 D 175701 D Common Stock, par value $0.00001 per share 2024-05-03 4 S 0 847 76.0743 D 174854 D Stock Option (Right to Buy) 4.68 2024-05-03 4 M 0 4249 0.00 D 2021-03-31 2030-03-31 Common Stock 4249 4251 D Stock Option (Right to Buy) 4.88 2024-05-03 4 M 0 30000 0.00 D 2023-01-03 2032-01-03 Common Stock 30000 60000 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.97 to $73.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.98 to $74.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.985 to $75.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.995 to $76.135, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. /s/ Michael Morneau as Attorney-in-Fact 2024-05-03